TXNIP deletion also has beneficial effects in the context other tissues affected by diabetes complications including diabetic cardiomyopathy (26, 27), nephropathy (28, 29), retinopathy (30, 31), and neuropathy (32, 33) further supporting the notion of TXNIP representing an attractive target for systemic inhibition in the treatment of diabetes (17, 34). The gene discussed is TXNIP; the disease is diabetic cardiomyopathy.